Ray brings over 25 years of experience working in executive finance roles at high tech and pharmaceutical companies worldwide.
VANCOUVER, British Columbia – December 2, 2020 – Aspect Biosystems, a biotechnology company developing bioprinted therapeutics, is pleased to announce the appointment of Ray Smith as its new Chief Financial Officer. In his role as Chief Financial Officer, Ray will assume leadership responsibilities for financial management and business operations.
“Since leaving the University of British Columbia’s campus and launching our commercial operations in 2016, Aspect has established itself as a global leader in regenerative medicine and 3D bioprinting,” said Tamer Mohamed, CEO of Aspect Biosystems. “Ray’s strong expertise across finance, corporate development, and strategy will be a huge asset to our company as we enter into the next phase of our growth and evolution as a deep technology-enabled therapeutics company.”
"Aspect Biosystems has a technology and team with huge potential to make a real difference in patients’ lives,” said Ray Smith, Chief Financial Officer, Aspect Biosystems. “I’m excited to be part of this team and contribute to our growth in the years ahead.”
Ray is a seasoned financial executive with over 25 years of experience leading finance teams in rapidly growing businesses. After completing his studies in Mathematics and Computation from Loughborough University in the UK, he started his career at Ernst & Young (EY), where he was qualified as a Chartered Accountant. After his time at EY, he joined Eurand, a global specialty pharmaceutical company. As VP, Finance at Eurand, he helped grow the US company from 70 to 330 employees, increase annual revenue from single digits to over $100M, develop and launch Eurand’s first clinical product generating a new $100M revenue stream, and complete a $110M IPO on the NASDAQ in 2007.
Ray was later CFO at Recon Instruments, the world leader in Heads-up Display technology for sports environments that was acquired by Intel for over $175M. Most recently he was CFO of Cross Pacific Capital Partners and several of their portfolio companies in the high-tech space. During this period, he played a leading role in raising significant capital from multiple sources including Lenovo, M Ventures (the venture capital fund of Merck KGaA), and 3M while providing strong financial and operational leadership to multiple corporations across several countries.
About Aspect Biosystems
Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development and commercialization of 3D bioprinted tissues. Internally, Aspect is advancing multiple regenerative medicine programs, initially focused on metabolic, pancreas, and liver diseases and strategically partnering with global biopharma leaders to bring bioprinted therapeutics to the clinic. Learn more at www.aspectbiosystems.com.